company background image
ORGO

Organogenesis HoldingsNasdaqCM:ORGO Stock Report

Market Cap

US$1.4b

7D

-12.6%

1Y

130.0%

Updated

15 Oct, 2021

Data

Company Financials +
ORGO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance3/6
Financial Health5/6
Dividends0/6

ORGO Overview

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.

Organogenesis Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Organogenesis Holdings
Historical stock prices
Current Share PriceUS$10.95
52 Week HighUS$3.45
52 Week LowUS$24.34
Beta1.79
1 Month Change-29.31%
3 Month Change-24.22%
1 Year Change130.04%
3 Year Changen/a
5 Year Changen/a
Change since IPO-18.53%

Recent News & Updates

Sep 27
Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Could Be 24% Above Their Intrinsic Value Estimate

Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Could Be 24% Above Their Intrinsic Value Estimate

In this article we are going to estimate the intrinsic value of Organogenesis Holdings Inc. ( NASDAQ:ORGO ) by...

Shareholder Returns

ORGOUS BiotechsUS Market
7D-12.6%1.0%2.0%
1Y130.0%12.4%27.6%

Return vs Industry: ORGO exceeded the US Biotechs industry which returned 12.4% over the past year.

Return vs Market: ORGO exceeded the US Market which returned 27.6% over the past year.

Price Volatility

Is ORGO's price volatile compared to industry and market?
ORGO volatility
ORGO Beta1.79
Industry Beta0.98
Market Beta1

Stable Share Price: ORGO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ORGO's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1985910Gary Gillheeneyhttps://organogenesis.com

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications.

Organogenesis Holdings Fundamentals Summary

How do Organogenesis Holdings's earnings and revenue compare to its market cap?
ORGO fundamental statistics
Market CapUS$1.43b
Earnings (TTM)US$70.06m
Revenue (TTM)US$433.35m

20.1x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ORGO income statement (TTM)
RevenueUS$433.35m
Cost of RevenueUS$103.92m
Gross ProfitUS$329.44m
ExpensesUS$259.38m
EarningsUS$70.06m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 09, 2021

Earnings per share (EPS)0.54
Gross Margin76.02%
Net Profit Margin16.17%
Debt/Equity Ratio39.0%

How did ORGO perform over the long term?

See historical performance and comparison

Valuation

Is Organogenesis Holdings undervalued compared to its fair value and its price relative to the market?

21.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ORGO ($10.95) is trading below our estimate of fair value ($13.86)

Significantly Below Fair Value: ORGO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ORGO is good value based on its PE Ratio (20.1x) compared to the US Biotechs industry average (23.6x).

PE vs Market: ORGO is poor value based on its PE Ratio (20.1x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: ORGO is poor value based on its PEG Ratio (1.1x)


Price to Book Ratio

PB vs Industry: ORGO is overvalued based on its PB Ratio (7.9x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Organogenesis Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

17.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORGO's forecast earnings growth (17.9% per year) is above the savings rate (2%).

Earnings vs Market: ORGO's earnings (17.9% per year) are forecast to grow faster than the US market (15.1% per year).

High Growth Earnings: ORGO's earnings are forecast to grow, but not significantly.

Revenue vs Market: ORGO's revenue (9.7% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: ORGO's revenue (9.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ORGO's Return on Equity is forecast to be low in 3 years time (17.8%).


Past Performance

How has Organogenesis Holdings performed over the past 5 years?

41.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ORGO has a high level of non-cash earnings.

Growing Profit Margin: ORGO became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ORGO has become profitable over the past 5 years, growing earnings by 41.2% per year.

Accelerating Growth: ORGO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ORGO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: ORGO's Return on Equity (39.2%) is considered high.


Financial Health

How is Organogenesis Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: ORGO's short term assets ($201.8M) exceed its short term liabilities ($84.5M).

Long Term Liabilities: ORGO's short term assets ($201.8M) exceed its long term liabilities ($92.1M).


Debt to Equity History and Analysis

Debt Level: ORGO's debt to equity ratio (39%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ORGO's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: ORGO's debt is well covered by operating cash flow (71.1%).

Interest Coverage: ORGO's interest payments on its debt are well covered by EBIT (7.5x coverage).


Balance Sheet


Dividend

What is Organogenesis Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ORGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORGO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ORGO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Gary Gillheeney (66 yo)

7.75yrs

Tenure

US$2,481,535

Compensation

Mr. Gary S. Gillheeney, Sr. serves as the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018. Mr. Gillheeney served as Organog...


CEO Compensation Analysis

Compensation vs Market: Gary's total compensation ($USD2.48M) is below average for companies of similar size in the US market ($USD3.56M).

Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ORGO's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: ORGO's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ORGO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22%.


Top Shareholders

Company Information

Organogenesis Holdings Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Organogenesis Holdings Inc.
  • Ticker: ORGO
  • Exchange: NasdaqCM
  • Founded: 1985
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.434b
  • Shares outstanding: 128.58m
  • Website: https://organogenesis.com

Number of Employees


Location

  • Organogenesis Holdings Inc.
  • 85 Dan Road
  • Canton
  • Massachusetts
  • 2021
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/15 23:19
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.